Susceptibility, tumor progression and resistance
Pujana’s Lab

DESCRIPTION

Targeting cancer complexity at origin and progression

Our research is focused on better understanding breast cancer initiation and, from acquired knowledge, to assess targeted prevention strategies. In parallel, we study pan-cancer vulnerabilities and the connection to a rare, lung metastatic disease, lymphangioleiomyomatosis (LAM).

Group members

Miquel Angel Pujana

Group leaders

Principal investigator

Francesca Mateo

Researchers

Research assistant

Roderic Espín

Young investigators

PhD student

Lara Ruiz

Young investigators

PhD student

Arzoo Shabbir

Young investigators

PhD student

Luís Alfaro

Young investigators

PhD student

Publications

Cabergoline Suppresses Postpartum Breast Cancer by Enhancing Mammary Gland Involution in Brca1-Mutant Mice and Is Associated with Reduced Risk in Younger Women

15 de October de 2026/in Pujana's Lab/by

Cancer Discov. 2026 Oct 15. doi: 10.1158/2159-8290.CD-26-0187. Online ahead of print. ABSTRACT Breast cancer that arises in the postpartum period often carries a poor prognosis and urgently requires chemoprevention strategies, particularly for women at elevated risk. Here, we report that a single post-lactation dose of cabergoline, a dopaminergic agonist that blocks prolactin secretion, delays the […]

Aneuploidy selects for the acquisition of driver genes in breast cancer

8 de July de 2026/in Pujana's Lab/by

Nature. 2026 Jul 8. doi: 10.1038/s41586-026-10752-9. Online ahead of print. ABSTRACT Chromosome instability is highly prevalent in cancer and drives large-scale chromosomal imbalances, known as aneuploidies1-4. How aneuploidy contributes to tumorigenesis remains difficult to study due to the vast numbers of genes affected. Here we established a CRISPR knockout- and activation-linked assay (CRISPR-KOALA), enabling high-throughput […]

Exploring glucocorticoid receptor signalling in lymphangioleiomyomatosis

30 de June de 2026/in Pujana's Lab/by

ERJ Open Res. 2026 Jun 29;12(3):01285-2025. doi: 10.1183/23120541.01285-2025. eCollection 2026 May. ABSTRACT BACKGROUND: Lymphangioleiomyomatosis (LAM) is a rare, low-grade neoplasm that causes progressive cystic lung destruction and is often associated with renal angiomyolipomas (AMLs). Given evidence of pleiotropy linking LAM risk to pulmonary traits, we investigated whether glucocorticoid receptor (GR) signalling might influence LAM biology […]

Long-term outcomes of sirolimus therapy in sporadic and tuberous sclerosis complex-associated lymphangioleiomyomatosis: a retrospective cohort study

12 de June de 2026/in Pujana's Lab/by

Pol Arch Intern Med. 2026 Jun 12:17320. doi: 10.20452/pamw.17320. Online ahead of print. ABSTRACT INTRODUCTION: Sirolimus is the standard disease-modifying therapy for lymphangioleiomyomatosis (LAM), but long-term routine-care data integrating pulmonary, lymphatic, extrapulmonary, and biomarker outcomes remain limited. OBJECTIVES: To assess long-term effectiveness and safety of sirolimus in routine clinical practice. PATIENTS AND METHODS: We retrospectively […]

Advancing Cancer Prevention through Precision Prediction

1 de April de 2026/in Pujana's Lab/by

Cancer Discov. 2026 Apr 1;16(4):647-650. doi: 10.1158/2159-8290.CD-25-2235. ABSTRACT Emerging knowledge, integrative frameworks, and multidisciplinary partnerships together create an unprecedented opportunity to advance cancer prevention through precision. By combining multimodal risk assessment with causal biological insight and dynamic models of early carcinogenesis, precision prevention can enable actionable, equitable, and acceptable preventive and interception strategies. PMID:41918357 | […]

Research Projects

The group works and collaborates to decipher the systems mechanisms of cancer development and progression, with the aim of developing more precise preventive and therapeutic approaches. The group combines in silico and wet-lab studies for the purpose of identifying cancer principles and vulnerabilities.

Collaborations

CIMBA – Consortium of Investigators of Modifiers of BRCA1/2

https://cimba.ccge.medschl.cam.ac.uk/

Lobular Breast Cancer

https://lobsterpot.eu/

BRCA1 breast cancer

Khokha Lab

https://medbio.utoronto.ca/faculty/khokha

Hakem Lab

https://medbio.utoronto.ca/faculty/hakem

Maxwell Lab

https://www.bcchr.ca/cmaxwell

Serra Lab

https://vhio.net/biosketch-violeta-serra/

Cancer biology

Schramek Lab

https://schramek.lunenfeld.ca/

Li Lab

https://lilab.smhs.gwu.edu/

Barcellos-Hoff Lab

https://barcelloshofflab.ucsf.edu/principal-investigator

Cancer genetics

De Cid Lab – GCAT

http://www.gcatbiobank.org/

LAM research

Johnson Lab – LAM UK

https://www.nottingham.ac.uk/medicine/people/simon.johnson

Elżbieta Radzikowska

National Tuberculosis and Lung Diseases Research Institute, Poland

Kwiatkowski Lab

https://www.kwiatkowskilab.org/

AELAM

https://www.aelam.org/

VHIR

https://vhir.vallhebron.com/en/research/pneumology

Molina Lab

https://idibell.cat/en/research/translational-medicine-area/cardiovascular-respiratory-and-systemic-diseases-and-cellular-aging-program/pneumology/

Susceptibility, tumor progression and resistancePujana’s Lab

DESCRIPTION

Miquel Angel Pujana

Group leaders

Francesca Mateo

Researchers

Roderic Espín

Young investigators

Lara Ruiz

Young investigators

Arzoo Shabbir

Young investigators

Luís Alfaro

Young investigators

CONTACT US

Susceptibility, tumor progression and resistance
Pujana’s Lab